Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02248090 · ClinicalTrials.gov registry record · Phase 1
AZD9496 First Time in Patients Ascending Dose Study
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
NCT02248090 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 45 participants.
The verdict
NCT02248090, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
Study Summary
This is a phase 1 open label multicentre study of AZD9496 administered orally in patients with advanced ER+ HER2 negative breast cancer. The study design allows an escalation of dose with intensive safety monitoring to ensure the safety of patients. The study will determine the maximum tolerated dose. In addition, expansion cohort(s) at potential therapeutic dose(s) in patients with or without ESR1 mutations will be enrolled to further determine the safety, tolerability, pharmacokinetics and biological activity of AZD9496
Interventions
- DRUG AZD9496
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2014-10-22 |
| Est. Completion | 2019-04-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02248090
The ClinicalTrials.gov registry entry for NCT02248090 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AZD9496 is the first listed.
NCT02248090 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02248090 about?
NCT02248090 is a clinical study titled "AZD9496 First Time in Patients Ascending Dose Study". This is a phase 1 open label multicentre study of AZD9496 administered orally in patients with advanced ER+ HER2 negative breast cancer. The study design allows an escalation of dose with intensive safety monitoring to ensure the safety of patients. The study will determine the maximum tolerated dos...
What is the current status of trial NCT02248090?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2014-10-22. Estimated completion is 2019-04-03.
What interventions are being tested in trial NCT02248090?
The interventions under investigation include: AZD9496 (DRUG).
Who is sponsoring clinical trial NCT02248090?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.